382 Phentermine
Alger, S.A., et al. “Beneficial Effects of Pharmacotherapy on Weight Loss, Depressive
Symptoms, and Eating Patterns in Obese Binge Eaters and Non-Binge Eaters.”
Obesity Research7 (1999): 469–76.
Brauer, L.H., et al. “Evaluation of Phentermine and Fenfluramine, Alone and in Com-
bination, in Normal, Healthy Volunteers.”Neuropsychopharmacology14 (1996):
233–41.
Devlin, M.J., et al. “Open Treatment of Overweight Binge Eaters with Phentermine and
Fluoxetine as an Adjunct to Cognitive-Behavioral Therapy.”International Journal
of Eating Disorders28 (2000): 325–32.
Douglas, A. “Plasma Phentermine Levels, Weight Loss and Side-Effects.”International
Journal of Obesity7 (1983): 591–95.
Griffen, L., and M. Anchors. “The ‘Phen-Pro’ Diet Drug Combination Is Not Associated
with Valvular Heart Disease.”Archives of Internal Medicine158 (1998): 1278–79.
Hoffman, B.F. “Diet Pill Psychosis: Follow-up after 6 Years.”Canadian Medical Associ-
ation Journal129 (1983): 1077–78.
Jones, K.L., et al. “Pregnancy Outcomes after First Trimester Exposure to Phentermine/
Fenfluramine.”Teratology65 (2002): 125–30.
Kokkinos, J., and S.R. Levine. “Possible Association of Ischemic Stroke with Phenter-
mine.”Stroke24 (1993): 310–13.
Langlois, K.J., et al. “Double-Blind Clinical Evaluation of the Safety and Efficacy of
Phentermine Hydrochloride (Fastin) in the Treatment of Exogenous Obesity.”
Current Therapeutic Research: Clinical and Experimental16 (1974): 289–96.